• Vaccine Name: RBD-rAAV-SARS-CoV
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Vaccine Ontology ID: VO_0004678
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Vector:
  • Vector name:
  • VO vector ID: VO_0000571
• Preparation: Inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant (Zheng et al., 2008).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Intranasal vaccination with RBD-rAAV (Zheng et al., 2008).
• Vaccine Immune Response Type: VO_0000287
• Immune Response: Induced production of IgG and IgA that exhibited neutralizing activity. Induced a markedly higher level of antigen specific IL-2+ T cells but a slightly lower level of IFN-γ+ T cells in the spleen, IFN-γ-producing CD3+/CD8+ T cells were significantly higher in the splenocytes of RBD-rAAV intranasally versus intramuscularly vaccinated mice. (Zheng et al., 2008)
• Challenge Protocol: Mice were challenged with 10^5 TCID50f SARS-CoV strain GZ50 (Zheng et al., 2008).
• Efficacy: RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses (Zheng et al., 2008).